- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06093815
Studio prospettico per valutare le risposte dei tessuti dopo l'iniezione con prodotti biostimolatori
Studio comparativo controllato, prospettico, in un unico sito, per identificare e valutare le risposte dei tessuti dopo l'iniezione con vari prodotti biostimolatori
The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study.
Safety endpoint: incidence of adverse events.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol.
Assessments under this protocol will include ultrasound of in vivo tissue.
Safety endpoint: incidence of adverse events.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Marbella, Spagna
- Ocean Clinic - Av. Ramon y Cajal 7, 29601
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy male & females; 22 to 65 years of age.
- Voluntary participation
- Ability to comprehend and provide informed consent.
- Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period.
- Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period.
- Participants agree NOT to undergo any surgical treatments in the treatment area during the study period.
- Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.
Exclusion Criteria:
- Any previous surgery in the abdominal area.
- Any previous treatment in the abdominal area.
- Planning to receive treatment of any kind in the abdominal area.
- Acute inflammatory process and/or infection at the injection site.
- Treatment of skin area with dermatosis.
- Eczema, exanthema or open wounds.
- Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study.
- Any contraindication to treatment with biostimulatory products based on the product's IFU.
- Previous pregnancy or intending to become pregnant during study participation.
- Known hypersensitivity to biostimulatory products or any of their formulation ingredients.
- Allergic reaction to topical and local anesthetics.
- Currently using anticoagulant therapy.
- Haemophilia / bleeding disorder.
- Chemotherapy, radiotherapy or high doses of corticosteroids.
- Systemic infection (e.g., hepatitis).
- Uncontrolled diabetes mellitus.
- Any medical condition that may put the participant at increased risk with exposure to biostimulatory products.
- Any medication that might modulate the immune response.
- Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant.
- Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating.
- Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study.
- Injection of local anesthesia into the flap during abdominoplasty surgery.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm 1
Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse(+) undiluted, Radiesse diluted 1:1, Radiesse diluted 1:2, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Sperimentale: Arm 2 - Radiesse Classic (1:1 Dilution)
Five participants in Arm 2 will receive Radiesse Classic diluted 1:1 with sterile saline (CaHA-CMC 1:1) and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Sperimentale: Arm 2 - Sculptra
Five participants in Arm 2 will receive Sculptra diluted with 5 mL of sterile saline and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Arm 1 - Ultrasound Analyses - Skin Thickness (mm)
Lasso di tempo: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Elastosis
Lasso di tempo: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Microvascular Formation
Lasso di tempo: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at the injection site and reported according to the study-defined category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Skin Thickness (mm)
Lasso di tempo: 6 months prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Elastosis
Lasso di tempo: 6 months prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Microvascular Formation
Lasso di tempo: 6 months prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at injection site and reported according to the study-defined category/grade. |
6 months prior to surgery timepoint(s)
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety Assessment
Lasso di tempo: through study completion, an average of 6 months
|
Any patient- or investigator-observed adverse event |
through study completion, an average of 6 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Ann P Marx, MD, Merz North America, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Disturbi indotti chimicamente
- Effetti collaterali correlati al farmaco e reazioni avverse
- Stravaso di materiali diagnostici e terapeutici
- Condizioni patologiche, segni e sintomi
- Reazione al sito di iniezione
- Terapie
- Rotte della somministrazione di droga
- Terapia farmacologica
- Iniezioni
Altri numeri di identificazione dello studio
- M900311010
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
individual data will be summarized for analyses
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .